• Completed $203 million capital raise
• Advanced key clinical trials, including SECuRE, AMPLIFY, and DISCO
• Presented data at major conferences, including SNMMI and ASCO

Clarity Pharmaceuticals announced its quarterly activities and cash flow report for the three months ending June 30, 2025. The company remains well-funded, with a cash position of $84.1 million at the end of the quarter, which was further bolstered by a $203 million placement completed in late July. This placement was executed at a premium to the company's previous closing price and 15-day VWAP. Clarity made significant progress across its clinical pipeline during the quarter. In the SECuRE trial, the company successfully treated the first participant in the Cohort Expansion Phase with a combination of 67Cu-SAR-bisPSMA and enzalutamide. The AMPLIFY diagnostic trial of 64Cu-SAR-bisPSMA in biochemical recurrence of prostate cancer also commenced enrolment, with the first participant imaged in May. Additionally, the Co-PSMA Investigator-Initiated Trial led by Prof. Louise Emmett completed enrolment of 50 patients, with initial results expected in the coming months. Clarity also reported positive topline data from the DISCO trial of 64Cu-SARTATE in neuroendocrine tumors, where the product demonstrated superior lesion detection compared to the standard-of-care 68Ga-DOTATATE. Similarly, the SABRE trial of 64Cu-SAR-Bombesin in PSMA-negative biochemical recurrence of prostate cancer showed the potential of this agent to detect lesions missed by standard imaging. Clarity plans to progress these programs, focusing on high-priority assets like SAR-bisPSMA, SARTATE, and SAR-Bombesin, while closing trials in paediatric neuroblastoma and PSMA-negative metastatic castration-resistant prostate cancer. The company also strengthened its supply and manufacturing capabilities through agreements for copper-64 and 64Cu-SAR-bisPSMA production.

Clarity Pharmaceuticals remains focused on progressing its key clinical-stage assets, including 64/67Cu-SAR-bisPSMA, 64Cu-SARTATE, and 64Cu-SAR-Bombesin, towards commercialization. The company plans to initiate a registrational Phase III study for 64Cu-SARTATE in neuroendocrine tumors and continue advancing its other programs through late-stage clinical trials.